The controversial covid pass keeps making headlines, and the latest news comes from Europe. It’s been just revealed that the European Commission is proposing to extend the EU digital covid pass by one more year. Check out the latest official reports below.
The other day, it’s been revealed that the European Commission is proposing to extend the EU Digital COVID Certificate by a year, until 30 June 2023.
The official notes begin by saying the following:
“The COVID-19 virus continues to be prevalent in Europe and at this stage it is not possible to determine the impact of a possible increase in infections in the second half of 2022 or of the emergence of new variants. Extending the Regulation will ensure that travellers can continue using their EU Digital COVID Certificate when travelling in the EU where Member States maintain certain public health measures.”
On February 3rd, the official notes were revealing that the Commission is adopting the proposal today to make sure the European Parliament and the Council can conclude the legislative procedure in time before the current Regulation expires.
More than that, it’s been also revealed that in addition to the extension of the EU Digital COVID Certificate Regulation until June 2023, the Commission also proposes some limited amendments.
Check out these amendments below:
We suggest that you check out the complete notes on the official website in order to learn all the available details.
The latest on coronavirus
The novel coronavirus keeps governing our lives and we’ve been sharing with you the latest reports on all related issues. The other day, we were revealing that Daily Mail noted the fact that Pfizer and its partner, BioNTech, have officially submitted data to the U.S. Food and Drug Administration (FDA) to have its vaccine authorized for use in children aged six months to four years old.
The company has just revealed the planned move, following reports earlier in the day that the regulatory agency was urging them to submit an application soon.
Pfizer makes efforts to intervene in an important lawsuit
Now, the important press agency Reuters notes the following:
“Pfizer Inc wants to intervene in a Texas federal lawsuit seeking information from the U.S. Food and Drug Administration used in licensing the company’s COVID-19 vaccine, a litigation move that plaintiffs who are suing for the data say is premature.”
It’s been reported that Pfizer’s lawyers at DLA Piper told U.S. District Judge Mark Pittman on Jan. 21 it wanted a role in the proceedings to help the FDA avoid “inappropriately” disclosing trade secret and confidential commercial information.
More publications are picking up on the news and revealing that the FDA is asking the court to delay the first 55,000 page production until May.